Mometasone Furoate Sinus Implant Use in Patients with Nasal Polyps: An Updated Descriptive Analysis

In this report we estimated the incidence rates of ocular adverse events (cataract, glaucoma, ocular hypertension and diminished visual acuity) and nasal septal perforation among individuals with new use of a 1350 mcg mometasone furoate nasal stent implant (Sinuva®) and among individuals with new use of a 370 mcg mometasone furoate nasal stent implant (Propel®) in the Sentinel Distributed Database (SDD). Additionally, we estimated the background rates of glaucoma and cataract among individuals with evidence of repeat use of the 1350 mcg mometasone furoate nasal stent implant (Sinuva®).

We distributed this query to 14 Sentinel Data Partners on July 22, 2024. The study period includes data from December 1, 2017 through January 31, 2024.